The patent badge is an abbreviated version of the USPTO patent document. The patent badge does contain a link to the full patent document.

The patent badge is an abbreviated version of the USPTO patent document. The patent badge covers the following: Patent number, Date patent was issued, Date patent was filed, Title of the patent, Applicant, Inventor, Assignee, Attorney firm, Primary examiner, Assistant examiner, CPCs, and Abstract. The patent badge does contain a link to the full patent document (in Adobe Acrobat format, aka pdf). To download or print any patent click here.

Date of Patent:
Dec. 07, 2021

Filed:

Feb. 16, 2017
Applicant:

Research Development Foundation, Carson City, NV (US);

Inventors:

Xinjian Lin, La Jolla, CA (US);

Xiying Shang, La Jolla, CA (US);

Stephen B. Howell, La Jolla, CA (US);

Assignee:

Research Development Foundation, Carson City, NV (US);

Attorney:
Primary Examiner:
Int. Cl.
CPC ...
A61K 47/65 (2017.01); C12N 9/64 (2006.01); C12N 9/52 (2006.01); A61K 47/68 (2017.01); C07K 14/435 (2006.01); C07K 14/59 (2006.01); C12N 9/96 (2006.01); A61K 48/00 (2006.01);
U.S. Cl.
CPC ...
C12N 9/6467 (2013.01); A61K 47/65 (2017.08); A61K 47/6889 (2017.08); C07K 14/43504 (2013.01); C07K 14/59 (2013.01); C12N 9/52 (2013.01); C12N 9/6424 (2013.01); C12N 9/96 (2013.01); C12Y 304/21079 (2013.01); C12Y 304/2207 (2013.01); C12Y 304/22007 (2013.01); A61K 48/00 (2013.01); C07K 2319/00 (2013.01); C07K 2319/21 (2013.01); C07K 2319/33 (2013.01); C07K 2319/40 (2013.01); C07K 2319/55 (2013.01); C07K 2319/70 (2013.01); C07K 2319/74 (2013.01); C07K 2319/90 (2013.01);
Abstract

The present invention is directed generally to cell-targeted cytotoxic constructs comprising a targeting polypeptide, a linking polypeptide and a cytotoxic polypeptide. Preferably, (a) the targeting polypeptide is a R-spondin1 (RSPO1), R-spondin2 (RSPO2) or yoked chorionic gonadotropin (YCG), the linking polypeptide comprises LPXT (SEQ ID NO: 56) or NPXT (SEQ ID NO: 60) as well as others, where X is any amino acid, the linking polypeptide being positioned between the targeting ligand and (c) the cytotoxic moiety is an auristatin or a truncated serine protease, the serine protease having an IIGG (SEQ ID NO: 91), IVGG (SEQ ID NO: 92) or ILGG (SEQ ID NO: 93) at its N-terminus. Such constructs can be used in methods for targeted cell killing such as for treatment cell of proliferative diseases (e.g., cancer).


Find Patent Forward Citations

Loading…